Compare Gilead Sciences, Inc. (GILD) vs iShares iBoxx $ High Yield Corporate Bond ETF (HYG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs iShares iBoxx $ High Yield Corporate Bond ETF — how do they compare? Gilead Sciences, Inc. trades at $147.94 (market cap $182.40B), while iShares iBoxx $ High Yield Corporate Bond ETF trades at $77.16 (market cap $17.89B). The key difference: Gilead Sciences, Inc. is far larger — about 10.2× iShares iBoxx $ High Yield Corporate Bond ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while iShares iBoxx $ High Yield Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and iShares iBoxx $ High Yield Corporate Bond ETF for 59 Days on average.
| GILD | HYG | |
|---|---|---|
Market Cap | $182.40B | $17.89B |
Volume | 4,469,821 | 44,866,592 |
Sector | Health | Fixed Income |
52-Week High | $155.80 | $81.28 |
52-Week Low | $116.74 | $76.90 |
Typical Hold Time | 111 Days | 59 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
HYG trades at $77.18, down 0.12% with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings but faces pressure from rising Treasury yields impacting high-yield bond valuations. Recent dividend payments of $0.34-$0.44 provide income support amid market volatility.
The outlook remains challenged by persistent bond market selloffs and higher interest rates, though the current yield environment may attract income-seeking investors. Key risks include further Fed tightening and economic slowdown impacting corporate credit quality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →
